In this study, keratin‐based hydrogels incorporating calcium ions were developed to effectively deliver atorvastatin, showing potential for localized anti‐fibrotic therapy through controlled drugrelease and maintaining drug bioactivity in vitro, supported by thorough physicochemical and mechanical characterization.
23 citations
,
July 2021 in “International Journal of Pharmaceutics”
This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.
43 citations
,
July 2016 in “European journal of pharmaceutical sciences”
This study found that dexamethasone-loaded Eudragit® L 100 nanoparticles displayed controlled drugrelease depending on pH levels, with minimal toxicity to human fibroblasts.
January 2025 in “International Journal of Research and Innovation in Applied Science”
This study aimed to enhance the skin penetration of minoxidil by encapsulating it in glycerosomal vesicles, offering a potential improvement in transdermal drug delivery for treating androgenetic alopecia. Results of the investigation were not reported.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.
Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.